CMS Modifies Permanent P-Code Allowing Outpatient Hospital Billing of the Verax PGD® Test
The decision means a PGD® tested apheresis platelet will receive the exact same reimbursement as a pathogen reduced platelet
Specifically, the CMS revised the HCPCS code established in 2016 for pathogen-reduced platelets (P9072) to include the use of pathogen-reduction technology or rapid bacterial testing. The descriptor for this code will be revised to read: P9072 (Platelets, apheresis, pathogen reduced or rapid bacterial tested, each unit).
The revised code and updated payment rate, outlined below, was published by CMS on
Revised CY 2017 |
Long Descriptor |
Final CY 2017 |
||||
P9072 |
Platelets, apheresis, pathogen reduced or |
|
||||
“We are extremely pleased the CMS has established a permanent P-Code for rapid bacterial testing, as it signals the importance this testing plays in the safety of our nation’s blood supply and provides a path for reimbursement for rapid testing,” said
The Verax Platelet PGD® Test is a simple,
“The Verax Platelet PGD® test is unique in that it is the only
About
Verax is the producer of the Platelet PGD® Test, the only test for bacterial contamination in platelets granted a Safety Measure claim by the
About the
1 81 Fed. Reg. 79562, 79577 (
View source version on businesswire.com: http://www.businesswire.com/news/home/20161115006028/en/
SVP/Marketing & Business Development
[email protected]
Source:
House Energy & Commerce Subcommittee Receives Testimony from Consumer Reports
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News